昊海生科展馆视觉中国供图 羊城晚报记者 汪海晏 近日，上海昊海生物科技股份有限公司（以下简称"昊海生科"）发布公告称，公司控股股东、实际控制 人之一蒋伟因涉嫌内幕交易，被中国证监会立案调查，但此事与公司股票无关。 不过，尽管蒋伟本人并不在上市公司担任具体职务，也不参与公司日常经营管理，公司日常运作由以侯 永泰、吴剑英为核心的专业管理团队负责。但作为创始人与实控人，蒋伟对公司发展方向有着深远影 响。 早期，昊海有限公司通过引入上海华源生命科学研究开发有限公司完成首次增资，切入医用透明质酸钠 （即玻尿酸）领域。此后，昊海生科开启频繁的并购扩张之路，在眼科领域，2015-2021年间接连收购 昊海生科在公告中特别强调："本次事项系对蒋伟先生个人的调查，其不参与公司日常经营管理，该事 项不会对公司日常经营活动产生重大影响。"尽管公司极力撇清与该事件的关系，但资本市场迅速作出 反应。截至5月9日收盘，A股昊海生科股价收报52元，下跌0.5%，总市值121亿元；港股股价则下跌 1.69%。 5月11日，羊城晚报记者就该事件对公司带来的影响、公司目前的应对措施、未来战略规划等相关问题 采访昊海生科，截至发稿未收到回复。 实 ...

证券代码：300121 证券简称：阳谷华泰 公告编号：2025-071 债券代码：123211 债券代码：阳谷转债 山东阳谷华泰化工股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东阳谷华泰化工股份有限公司（以下简称 "公司"、"上市公司"或"阳 谷华泰"）拟通过发行股份及支付现金方式购买波米科技有限公司（以下简称"波 米科技"或"标的公司"）100%股权并募集配套资金（以下简称"本次交易"或 "本次重组"）。 根据《上市公司重大资产重组管理办法》《上市公司监管指引第 7 号——上 市公司重大资产重组相关股票异常交易监管》《公开发行证券的公司信息披露内 容与格式准则第 26 号——上市公司重大资产重组》 《监管规则适用指引——上市 类第 1 号》等法律、法规的要求，上市公司对本次交易相关内幕信息知情人买卖 上市公司股票的自查报告进行了核查，具体如下： 一、本次交易的内幕信息知情人买卖股票情况的自查期间 本次交易自查期间为自上市公司首次披露本次重组事项或就本次重组申请 股票停牌（孰早）前六个月至《山东阳谷华泰化工股份有限公司发行股份及支付 现金购 ...

Core Viewpoint - The company is facing significant challenges due to the investigation of its controlling shareholder for insider trading, alongside declining performance in key business segments and increasing competition in the industry [1][5][6]. Financial Performance - The company's overall revenue growth has slowed, with 2024 revenue at 2.698 billion (up 1.64% year-on-year) and net profit at 420 million (up 1.04% year-on-year) [2]. - In Q1 2025, revenue dropped to 619 million (down 4.25% year-on-year) and net profit to 90 million (down 7.41% year-on-year) [2]. - R&D expenses decreased significantly by 25.4%, while sales and management expense ratios increased by 0.54 and 1.52 percentage points, respectively [2]. Business Segmentation - The medical aesthetics segment showed weak growth, with 2024 revenue at 1.2 billion (44.38% of total), and hyaluronic acid product revenue at 742 million (up 23.23% year-on-year), but a sharp decline from 95.45% growth in 2023 [3]. - The ophthalmology segment reported revenue of 858 million (down 7.60% year-on-year), with intraocular lens revenue at 328 million (down 14.06% year-on-year), primarily impacted by a 60% price drop from the fourth national procurement [3]. - The orthopedics segment generated revenue of 457 million (down 4.11% year-on-year), with profits affected by price declines from provincial procurement for sodium hyaluronate injections [4]. Dividend and Market Concerns - The company's high dividend payouts have raised market concerns, with the controlling shareholder couple receiving approximately 344 million in cash dividends from 2019 to 2024, and the 2024 dividend accounting for 54.92% of net profit [4]. Industry Risks - The investigation into the controlling shareholder poses risks, including potential stock freezes or selling restrictions, which could undermine market confidence and highlight governance issues due to concentrated ownership [5][6]. - The company faces intense competition in the medical aesthetics sector, with rivals like Huaxi Biological and Aimeike, and pressure from new technologies impacting traditional markets [6]. - The normalization of centralized procurement is leading to a downward price trend for ophthalmology and orthopedics products, necessitating faster innovation to maintain profit margins [7]. Cash Flow and Asset Quality - Concerns regarding cash flow and asset quality are evident, with accounts receivable at 316 million (75.18% of net profit) and a low inventory turnover rate of 0.39 times [8]. - In Q1 2025, operating cash flow was 86 million, while cash outflow from investment activities was 179 million [8].

Core Viewpoint - The recent investigation of Jiang Wei, a major shareholder of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading is not expected to significantly impact the company's operations or stock performance [1][2]. Company Overview - Haohai Biological Technology is recognized for its "medical aesthetics + ophthalmology" business model, with a focus on high-margin products such as artificial lenses and medical-grade hyaluronic acid [2][3]. - The company is the first biopharmaceutical firm listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange's Sci-Tech Innovation Board [2]. Financial Performance - Revenue has shown consistent growth from 1.3 billion yuan in 2020 to 2.6 billion yuan in 2024, while net profit increased from 200 million yuan to 400 million yuan during the same period, despite a significant drop in 2022 [2][3]. - In 2024, the company reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, up 1.04% [3]. Market Challenges - The medical aesthetics and ophthalmology sectors are facing increased competition and price reductions due to national procurement policies, leading to stagnation in revenue growth for 2024 [3]. - The medical aesthetics segment has shown signs of growth fatigue, with revenues from medical beauty and wound care products increasing from 460 million yuan in 2021 to 1.2 billion yuan in 2024, but growth rates are declining [3]. Product Development - In July 2024, Haohai Biological Technology received approval for its fourth-generation hyaluronic acid product, Hai Mei Yue Bai, aimed at treating moderate to severe nasolabial folds, positioning it as a potential growth driver in the high-end medical aesthetics market [4]. - The product is priced at 13,800 yuan for 1ml and 19,800 yuan for 2ml, indicating a premium positioning [4]. Recent Performance - In the first quarter of 2024, the company experienced a decline in both revenue and net profit, with revenue at 619 million yuan, down 4.25%, and net profit at approximately 90.31 million yuan, down 7.41% [4].

Core Insights - A mysterious trader profited nearly $100 million in just two minutes before the announcement of "First Lady Coin" ($MELANIA) [1] - The coin was launched by Melania Trump, and 24 digital wallets purchased 16.7 million tokens worth $2.6 million shortly before the official announcement [1] - 81% of the tokens were sold within 12 hours after the announcement, resulting in a profit of $99.6 million [1] Group 1 - The initial purchase included $8.87 million in USDC and the remainder in SOL, a more volatile cryptocurrency [1] - "First Lady Coin" is classified as a speculative cryptocurrency without actual utility, exempting it from federal disclosure and insider trading regulations [1] - Early buyers, referred to as "snipers," can gain substantial profits if market interest surges, while retail investors face significant risks [1] Group 2 - One wallet spent $681,000 on the token just 64 seconds before the public announcement and made a profit of $39 million within 24 hours [2] - The entity behind the issuance of "First Lady Coin," MKT World LLC, has reportedly earned $64.7 million from fees and primary sales [2] - The official terms do not clarify whether MKT World is the issuer of the token or how profits are distributed among related parties [2]

对内幕交易的违法所得，此前没一罚三比较常见，没一罚六并不多见。 近日，江苏证监局公布了一则不太常见的罚单。赵某某内幕交易"永悦科技"，合计避损1124.5万元，被 证监局没收违法所得1124.5万元，并罚款6746.95万元，也就是没一罚六。此外，另一则处罚中，证监 局对其泄露内幕信息并建议他人买卖证券的行为处以250万元罚款，对内幕交易行为处以400万元罚款。 当事人辩称处罚过重，明显高于其他类案。江苏证监局称，量罚适当，不存在过重情形。赵某某多次利用 不同内幕信息从事内幕交易，交易金额、避损金额巨大，且其存在向他人泄露内幕信息并建议他人买卖相 关证券的违法行为，并引发他人大额内幕交易的严重后果。证监局也明确表示，本案与其他案件不具有可 比性。 证券时报·券商中国记者注意到，2024年8月，证监会在《2024年上半年证监会行政执法情况综述》中提 到，数知科技时任董事长张某利用职务之便获取内幕信息交易本公司股票，挑战法律底线，对其予以没一 罚六，合计罚没3500余万元，并采取终身市场禁入措施。 两则内幕信息 依据证券法的有关规定，江苏证监局对赵某某内幕交易"永悦科技"，赵某某泄露内幕信息并建议他人买卖 证券违 ...

对内幕交易的违法所得，此前没一罚三比较常见，没一罚六并不多见。 近日，江苏证监局公布了一则不太常见的罚单。赵某某内幕交易"永悦科技"，合计避损1124.5万元，被证监局没收违 法所得1124.5万元，并罚款6746.95万元，也就是没一罚六。此外，另一则处罚中，证监局对其泄露内幕信息并建议 他人买卖证券的行为处以250万元罚款，对内幕交易行为处以400万元罚款。 当事人辩称处罚过重，明显高于其他类案。江苏证监局称，量罚适当，不存在过重情形。赵某某多次利用不同内幕 信息从事内幕交易，交易金额、避损金额巨大，且其存在向他人泄露内幕信息并建议他人买卖相关证券的违法行 为，并引发他人大额内幕交易的严重后果。证监局也明确表示，本案与其他案件不具有可比性。 券商中国记者注意到，2024年8月，证监会在《2024年上半年证监会行政执法情况综述》中提到，数知科技时任董事 长张某利用职务之便获取内幕信息交易本公司股票，挑战法律底线，对其予以没一罚六，合计罚没3500余万元，并 采取终身市场禁入措施。 两则内幕信息 依据证券法的有关规定，江苏证监局对赵某某内幕交易"永悦科技"，赵某某泄露内幕信息并建议他人买卖证券违法 行为进行了 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002058 证券简称：威尔泰 公告编号：2025-015 上海威尔泰工业自动化股份有限公司 关于本次交易相关内幕信息知情人买卖股票情况自查报告的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大 遗漏。 上海威尔泰工业自动化股份有限公司（以下简称"上市公司 "、"公司 "或 "威尔泰"）拟向上海紫竹科技 产业投资有限公司（以下简称"紫竹科投 "）出 售上市公司持有的自动化仪器仪表业务资产组，紫竹科 投以现金作为对价进行支 付（以下简称"本次交易 "或"本次重组 "），本次交易构成重大资产出售。 根据《中华人民共和国证券法》《上市公司重大资产重组管理办法》《公开 发行证券的公司信息披露 内容与格式准则第 26 号一一上市公司重大资产重组》 《监管规则适用指引一一上市类第 1 号》等法 律、法规的要求，上市公司对本次 交易相关内幕信息知情人买卖上市公司A 股股票情况进行了核查， 具体如下： 一、本次交易相关主体买卖上市公司股票情况的自查期间及核查范围 （一） 自查期间 本次交易的内幕信息知情人买卖股票情况的 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has imposed administrative penalties on former executives of Xingmin Zhitong for insider trading, highlighting the importance of maintaining market fairness and investor confidence [2][5][7]. Group 1: Insider Trading Case - The CSRC disclosed that Zhao Feng, former chairman, and other executives engaged in insider trading by selling shares before the announcement of the termination of a restructuring plan, resulting in significant financial gains [2][3]. - Zhao Feng avoided losses of approximately 1.75 million yuan, while other executives, Cui Changsheng and Zhao Ping, avoided losses of about 520,000 yuan and 4.39 million yuan, respectively [3][6]. - The total penalties imposed on the three individuals exceeded 43 million yuan, including confiscation of illegal gains and fines [6]. Group 2: Company Background and Restructuring - Xingmin Zhitong, established in December 1999, is based in Longkou City, Shandong Province, and specializes in wheel production and intelligent connected vehicle hardware and data services [3]. - The company attempted a restructuring starting in May 2021 to acquire a 50.29% stake in Wuhan Zhongke Xinwei Information Technology Co., Ltd., but the deal ultimately failed in February 2022 due to a lack of agreement among parties [3][4]. Group 3: Market Impact and Regulatory Response - Following the announcement of the restructuring termination, Xingmin Zhitong's stock price fell from 5.46 yuan per share to 3.56 yuan, a decline of nearly 35% over two months [4]. - The CSRC emphasized its commitment to combating insider trading and market manipulation to protect investor rights and maintain market integrity [7][8].

嘿各位军事迷们，今儿咱们聊点不一样的——白宫那位又双叒叕摊上大事儿了！你们猜怎么着？咱们的川普大统领这回可能真要创造历史，成为 美利坚合众国开国以来头一遭因为"玩股票"被弹劾下台的总统！这剧情，比好莱坞大片还刺激啊！ 事情得从上周说起。4月2号那天，特朗普在白宫的椭圆形办公室里大笔一挥，签了个"对等关税"的行政令。好家伙，这命令一出，华尔街直接炸 锅了！道琼斯指数当天就摔了个大跟头，暴跌2.5%，创下了近五年来的单日最大跌幅。投资者们慌得一批，纷纷抛售股票，国债收益跟坐过山车 似的往上蹿，美元兑瑞士法郎都跌到十年谷底了。 正当市场哭天喊地的时候，咱们这位大统领4月9号突然在自家社交平台整了个大活："是时候抄底了！！！"后面还跟着个"DJT"的署名。这DJT可 不简单啊，既是特朗普名字的缩写，也是他旗下媒体科技集团的股票代码。更绝的是，这四个字刚发出去四小时，特朗普就宣布暂停对部分国家 的关税政策，美股立马跟打了鸡血似的，纳斯达克指数直接蹿出2008年金融危机以来的最大单日涨幅。 特朗普"炒股门"引爆弹劾危机？或成美国首位因金融下台总统！ 导语： 不过话说回来，弹劾特朗普可不是过家家。按美国宪法，先得众议院多数 ...